Accordingly, the inhibition of ETS transcription Factor ELK3 (ELK3), which is frequently overexpressed in aggressive breast cancers [159], led to PI3K/AKT/mTOR activation, which in turn enhanced the chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting protective autophagy [157]. Here, ELK3 is linked to breast carcinoma.